RBC Capital Remains a Buy on Topaz Energy Corp (TPZ)
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Harvey is a 5-star analyst with an average return of 12.6% and a 47.93% success rate. Harvey covers the Energy sector, focusing on stocks such as Whitecap Resources, Paramount Resources, and ARC Resources.
In a report released on May 6, Jefferies also reiterated a Buy rating on the stock with a C$29.00 price target.
The company has a one-year high of C$29.51 and a one-year low of C$21.00. Currently, Topaz Energy Corp has an average volume of 397K.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TPZ in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
RBC Capital Remains a Buy on Brookfield Infrastructure (BIP)
In a report released yesterday, Maurice Choy from RBC Capital maintained a Buy rating on Brookfield Infrastructure, with a price target of $40.00. The company's shares closed yesterday at $31.14. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Choy covers the Utilities sector, focusing on stocks such as Canadian Utilities A, ATCO Ltd Cl I NV, and Brookfield Infrastructure. According to TipRanks, Choy has an average return of 9.9% and a 66.67% success rate on recommended stocks. In addition to RBC Capital, Brookfield Infrastructure also received a Buy from Scotiabank's Robert Hope in a report issued yesterday. However, on July 29, TR | OpenAI – 4o reiterated a Hold rating on Brookfield Infrastructure (NYSE: BIP). Based on Brookfield Infrastructure's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.39 billion and a net profit of $106 million. In comparison, last year the company earned a revenue of $5.19 billion and had a net profit of $131 million
Business Insider
a day ago
- Business Insider
RBC Capital Reaffirms Their Hold Rating on Two Harbors (TWO)
In a report released on July 31, Kenneth Lee from RBC Capital maintained a Hold rating on Two Harbors, with a price target of $10.00. The company's shares closed yesterday at $9.78. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lee covers the Financial sector, focusing on stocks such as Invesco, Artisan Partners, and OneMain Holdings. According to TipRanks, Lee has an average return of 18.8% and a 74.25% success rate on recommended stocks. In addition to RBC Capital, Two Harbors also received a Hold from BTIG's Eric Hagen in a report issued yesterday. However, on July 29, Maxim Group reiterated a Buy rating on Two Harbors (NYSE: TWO).
Business Insider
a day ago
- Business Insider
RBC Capital Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics on July 31 and set a price target of $14.00. The company's shares closed yesterday at $15.91. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Abrahams is an analyst with an average return of -1.9% and a 43.69% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Vertex Pharmaceuticals, and Biogen. In addition to RBC Capital, Sarepta Therapeutics also received a Hold from TR | OpenAI – 4o's Dex Genotek in a report issued on July 30. However, on the same day, Citi maintained a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT). Based on Sarepta Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $744.86 million and a GAAP net loss of $447.51 million. In comparison, last year the company earned a revenue of $413.46 million and had a net profit of $36.12 million
